Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saving residual kidney function among haemodialysis patients receiving irbesartan
2008-001267-11Phase 3Completed
- Sponsor
- Department of Nephrology
- Start
- Aug 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in end-stage kidney disease (ESKD) and cardiac morbidity comparing Irbesartan with Placebo (2 arms). Primary endpoint: Reduced decline in residual kidney function. Started Aug 2008; status: completed.
02
Drugs
irbesartan
03
Conditions
end-stage kidney disease (ESKD)cardiac morbidity
Beyond the preview
Go deeper on 2008-001267-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001267-11.